



NEWS RELEASE

First-In-Human Study of Accommodating Intraocular Lens Set to Begin June 26, 2025

For Immediate Release

Calgary, Alberta – June 24, 2025 - Ocumetics Technology Corp. ("Ocumetics" or the "Company") (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to confirm the culmination of nearly two decades of research and development as it prepares for first-in-human (FIH) clinical studies of its revolutionary accommodating intraocular lens (the "Ocumetics Lens").

"This moment is nothing short of transformational," said Dean Burns, CEO of Ocumetics. "With clinical study site initiation set to begin this week, we are now taking the most significant step yet in bringing the Ocumetics Lens to market. What began as a dream to restore the youthful eye's natural ability to focus distant and near objects after cataract surgery is one step closer to becoming a reality. With a world class team, innovative technology, and unwavering determination, we are redefining what's possible in ophthalmology."

This summer marks a groundbreaking leap into the future of vision correction for Ocumetics as it initiates pivotal clinical trials of its accommodating intraocular lens – an implantable device that promises to provide patients worldwide with youthful, dynamic vision after cataract surgery.

The Company has made impressive strides leading to this pivotal moment:

- **Lens Design Freeze:** Final lens specifications are locked in, marking a major milestone in the journey from design and development to commercialization.
- **Manufacturing Completed:** Ocumetics successfully produced its first batch of lenses to be used for the upcoming FIH implantations.
- **Laboratory Testing:** Laboratory bench testing confirmed that the Ocumetics Lens provides sufficient accommodative power to restore a patient's ability to focus both distance and near objects without glasses.
- **Mexico City Selected as Trial Site:** Following an extensive review of available options, Mexico City was chosen as the first clinical trial site because of its strong infrastructure and experienced investigators.
- **Clinical Protocol Finalized and Submitted:** The protocol for a pivotal clinical study planned for this summer has been submitted to regulatory agencies.
- **Funding:** Ocumetics announced a private placement of up to \$2.1 million CAD, led by Numus Capital, to fund its clinical study, as well as ongoing research and development activities.

Backed by successful laboratory testing, validated manufacturing processes, and a finalized lens design, Ocumetics is entering the clinical testing phase with confidence. The FIH study in Mexico City will assess safety, performance, and visual outcomes in patients, laying the foundation for future regulatory submissions and eventual global commercialization.

Dr. Garth Webb, Founder and Chief Scientific Officer of Ocumetics, commented: “This is the culmination of years of tireless innovation. The Ocumetics Lens is not just a product; it represents a potential paradigm shift in vision restoration. We’re proud to be leading this next chapter in ophthalmic science.”

As Ocumetics turns its bold vision into clinical reality, the Company remains committed to transparency, innovation, and delivering life-changing solutions for patients seeking freedom from glasses and contact lenses.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns	Roger Jewett
President and Chief Executive Officer	Chief Financial Officer
(817) 874-7564	roger.jewett@ocumetics.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on

forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.